Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration

Retina

Volumn 26, Issue 4, 2006, Pages 383-390

  Spaide, Richard F ^a,b   Laud, Ketan ^a   Fine, Howard F ^a   Klancnik Jr , James M ^a   Meyerle, Catherine B ^a   Yannuzzi, Lawrence A ^a   Sorenson, John ^a   Slakter, Jason ^a   Fisher, Yale L ^a   Cooney, Michael J ^a  

^a EAR AND THROAT HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Vascular endothelial growth factor

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; PEGAPTANIB; MONOCLONAL ANTIBODY; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN A;

AGED; ARTICLE; DRUG SAFETY; ENDOPHTHALMITIS; FEMALE; HEART INFARCTION; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PARESTHESIA; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA LUTEA; RETINA TEAR; RETROSPECTIVE STUDY; SEIZURE; SUBRETINAL NEOVASCULARIZATION; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; VISION TEST; VISUAL ACUITY; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; IMMUNOLOGY; INJECTION; RETINA MACULA DEGENERATION; TREATMENT OUTCOME; VITREOUS BODY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 33745091547     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200604000-00001     Document Type: Article

References (20)

1. Spaide RF. Perspectives article. Rationale for combination therapies for choroidal neovascularization. Am J Ophthalmol 2006;141:149-156.
2. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982;100:912-918.
3. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after krypton laser photocoagulation for neovascular lesions of age-related macular degeneration. Arch Ophthalmol 1990;108:825-831.
4. Bressler NM. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials - TAP report 2. Arch Ophthalmol 2001;119:198-207.
5. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin in Photodynamic Therapy report 2. Am J Ophthalmol 2001;131:541-560.
6. Gragoudas ES, Adamis AP, Cunningham ET, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816.
7. Spaide R. New treatments for AMD. Ophthalmology 2006;113:160-161.
8. Genentech press release. http://www.gene.com/gene/news/press-releases/ display.do?method=detail&id=8727&categoryid=4 and http://www.gene.com/ gene/news/press-releases/display.do?method=detail&id=9307. Accessed February 6, 2006.
9. 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-444.
10. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3:391-400.
11. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twelve-week results of an uncontrolled open-label study. Ophthalmology 2005;112:1035-1074.
12. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:270-271.
13. Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:13-19.
14. Jackson TL, Antcliff RJ, Hillenkamp J, Marshall J. Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 2003;44:2141-2146.
15. Eyetech Pharmaceuticals, Pfizer, Inc. Dermatologic and Ophthalmic Drugs Advisory Committee meeting. Pegaptanib sodium injection (Macugen) [PowerPoint presentation]. Available at: http://www.fda.gov/ohrms/dockets/ac/04/slides/2004- 4053S1_01_EyeTech-Main.ppt. Accessed May 27, 2005.
16. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001;19:275-290.
17. http://www.fda.gov/medwatch/SAFETY/2005/Jan_PI/Avastin_PI.pdf. Accessed February 6, 2006.
18. Ma L, Francia G, Viloria-Petit A, et al. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res 2005;65:5365-5373.
19. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110:2372-2383.
20. Slakter JS, Bochow TW, D'Amico DJ, et al. Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. Ophthalmology 2006;113:3-13.